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Good evidence  exists  to  indicate  that  the  vasodilating 
effect of adenosine is mediated  by  cell  surface  receptors 
on vascular smooth muscle cells. The mechanism of 
transmembrane  signal  transduction  for adenosine, 
however, is not fully understood. Since cGMP is a 
second messenger known to mediate vasodilation, I 
have  examined the effect of adenosine on the  intracel- 
lular  concentration of cGMP in vascular  smooth muscle 
cells from  rat  aorta. I found that adenosine at  lo-’ to 
low5 M led to an  increase  in  intracellular cGMP levels 
in a dose-dependent  fashion. The effect of adenosine 
on cyclic guanosine  inorganic  monophosphate (cGMP) 
could be mimicked  by the A-type receptor  agonists W -  
cyclohexyladenosine and 5’-N-ethylcarboxamidoad- 
enosine  and  was  attenuated by the  A-receptor  antago- 
nist theophylline. The  order of potency of the adeno- 
sine analogues was N6-cyclohexyladenosine > 5’-N- 
ethylcarboxamidoadenosine > adenosine. These find- 
ings  suggest that  the effect of adenosine on cGMPi is 
mediated by A1-type cell surface  receptors.  Concerning 
the mechanism  by  which  adenosine could elevate 
cGMPi, I found that  the effect of adenosine on cGMPi 
was  potentiated by the cGMP phosphodiesterase-spe- 
cific inhibitor M & B 22948. Moreover, I found that 
N6-cyclohexyladenosine, 5’-N-ethylcarboxamidoad- 
enosine,  and  adenosine  stimulated a guanylate cyclase 
in homogenates of the  cultured smooth muscle cells in 
a dose-dependent  fashion with  the  same  order of po- 
tency as their  effects on cGMPi. Further  evidence  was 
obtained  to  indicate  that  adenosine  and its analogues 
stimulated a particulate guanylate cyclase activity, 
whereas  they  did not alter soluble guanylate cyclase 
activity. 
Since cGMP is known as a second  messenger  mediat- 
ing relaxation of vascular smooth muscle cells, the 
results  obtained  in  this  study could suggest that  aden- 
osine exerts  its  vasorelaxing  effect by activating  an Ai- 
receptor-linked  guanylate cyclase. 
Adenosine is considered an important regulator of blood 
flow in a variety of organs including heart (I), brain (2), 
skeletal muscle (3), and adipose tissue (4). This  function of 
adenosine is based  on  its  vasorelaxant effect on  arteries. The 
vasodilatory effect of adenosine  on blood vessels can be ob- 
served at  IO-’ to lo-” M both in i n  vivo and i n  vitro prepara- 
tions (5-7). Furthermore,  there  is good experimental evidence 
to indicate that adenosine exerts its vasorelaxant effect by 
occupying cell surface receptors  on vascular smooth muscle 
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cells (8-10). The mode of transmembrane signal transmission, 
however, according to  which activation of adenosine  receptors 
on  the cellular plasma  membrane leads to  relaxation of vas- 
cular  smooth muscle cells, is  not well understood (1-4). Two 
possible mechanisms by which adenosine could  induce  vaso- 
relaxation have been discussed. First, results obtained with 
mechanical (ll), electrophysiological (12,13),  and cell culture 
(14)  studies have indicated  that  adenosine  attenuates calcium 
influx into muscle cells. Therefore, it has been speculated 
that  adenosine might act  as a  calcium channel blocker. Recent 
experimental evidence, however, clearly  argues against a role 
of adenosine  as a calcium channel blocker (15-17). 
The second line of evidence is based on the observation 
that adenosine is capable of influencing adenylate cyclase 
activity  in a variety of tissues (18). It  has  been  found  that cell 
surface receptors for adenosine are linked to the adenylate 
cyclase in a way that occupancy of A,-receptors inhibits 
adenylate cyclase activity, whereas  occupancy of A2-receptors 
stimulates  this  activity (19). Since  cAMP is known as a second 
messenger that mediates relaxation of smooth muscle cells 
(20), it has been speculated that  the vasodilatory effect of 
adenosine could be mediated by a receptor-linked  activation 
of the  adenylate cyclase (21). A strong  argument  against  such 
signal transmission is, however, that  no  correlation  has been 
found  between  vasodilation and  tissue levels of cAMP  in  the 
presence of adenosine (1, 6, 22). Moreover, adenosine has 
been found to elevate levels of cAMP only at  concentrations 
that  are higher than lop4 M, whereas  the full relaxant effect 
of adenosine can be observed at concentrations that are 2 
orders of magnitude lower (6). 
A third signal transmission  system  that  mediates vasore- 
laxation involves cGMP  that is generated via an  activation of 
guanylate cyclase (23). Nitrocompounds (23) and  atrial  natri- 
uretic  peptide (24), for example, are  thought  to cause  vasodi- 
lation by stimulating a soluble and a membrane-bound gua- 
nylate cyclase, respectively. However,  apossible  role of 
cGMPi  in  the signal transmission of adenosine in vascular 
smooth muscle has  not been  considered so far. To my knowl- 
edge, the effect of adenosine on  cGMP  on  the level of isolated 
vascular smooth cells has not been  investigated to date. 
Therefore, the objective of this study was to investigate 
whether or not adenosine affects the intracellular level of 
cGMP  in vascular smooth muscle cells and, if so, to clarify 
the  mechanism by which adenosine  influences cGMPi. Using 
cultures of smooth muscle cells  derived  from rat  aorta, clear 
evidence was obtained  that  adenosine  stimulated a particulate 
guanylate cyclase in  these cells. Since the  activation of guan- 
ylate cyclase and  the rise in  cGMP occurred a t  concentrations 
of adenosine  that  are typical for its  vasorelaxant effect, stim- 
The abbreviations used are: cGMPi, cyclic guanosine inorganic 
monophosphate; SMC, smooth muscle cells; Hepes, 4-(2-hydroxy- 
ethyl)-1-piperazineethanesulfonic acid; CHA,  N6-cyclohexyladeno- 
sine; NECA, 5’-N-ethylcarboxamidoadenosine. 
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ulation of the  guanylate cyclase could be a signal  transmission 
system which mediates  adenosine's  vasorelaxant effect. 
MATERIALS AND  METHODS 
Cell Culture-Cultures of smooth muscle cells (SMC) from rat 
aorta were prepared using the modification described by Ross (26). 
Aortas were taken from male Sprague-Dawley rats (200-300-g  body 
weight). The vessels were thoroughly freed from adventitial tissue 
and cut  into small pieces. Tissue pieces  were seeded in 7-cmZ Petri 
dishes (Greiner, Niirtingen, Federal Republic of Germany) together 
with 1 ml of culture medium (RPMI 1640, 25 mM Hepes, 1 mg/ml 
insulin, 100 IU/ml penicillin, 100 pg/ml streptomycin, and  10% fetal 
bovine serum, all from Boehringer Mannheim) and incubated in a 
humidified atmosphere containing 5% CO, in air. Medium was re- 
moved after  7 days, and tissue explants were detached using a solution 
of Hanks' balanced salt solution (Ca2'- and  MP-free) supplemented 
with 5 mM EDTA and 0.25% trypsin (bovine pancreas, Sigma). Single 
cells were separated from tissue pieces by unit gravity sedimentation. 
Single cells were cloned by cell dilution using 24-microwell plates. 
Clones with apparent smooth muscle  cell  morphology  were used for 
further processing. Clonal cells were grown in 7-cm2 Petri dishes 
using the same culture conditions as described above. Cells were 
passaged after  they  had reached confluency. For experiments, con- 
fluent cultures between passages 6 and 10 were  used. 
Immunofluorescence Staining against Intermediate Filament Des- 
min-Demonstration of the intermediate filament desmin, which is 
considered to be specific for myogenic cells (27), was done according 
to Osborn and Weber (28). Upon passage, part of the cells were seeded 
on coverslips. Two hours after seeding, the cells were fixed with 
methanol, washed, and incubated with monoclonal antibody against 
desmin for 2 h a t  37 "C. Mouse monoclonal antibody against porcine 
desmin (29) was a generous gift from Dr. Mary Osborn. Thereafter, 
the cells were washed and incubated with fluorescein isothiocyanate- 
labeled goat antibody mouse y-globulin for 1 h at 37  "C. Immunoflu- 
orescence was examined using a Ployvar fluorescence microscope 
(Reichert-Jung, Austria). 
Determination of cGMP Levels-The  medium  was  removed  from 
the dishes, and cells were washed two times with prewarmed buffer 
(130 mM NaCl, 5 mM KCl, 2 mM CaC12, 1 mM MgCl,,  10 mM glucose, 
10 mM Hepes, pH 7.3). Then, 1 ml of this buffer with or without 
agents was added, and  the dishes were placed on a  heater  maintaining 
a  temperature of  37 "C. The incubation was stopped by removing the 
buffer and the addition of 1 ml of ice-cold buffer (5 mM potassium 
phosphate, 0.2 mM EDTA, 0.5 mM 3-isobutylmethylxanthine, 150 
mM KCl, pH 6.8). This buffer was quickly removed, and  the dishes 
were placed on an ice  block. Finally, the cells were scraped off in 0.4 
ml  of this buffer using a Teflon policeman. The obtained suspension 
was subsequently sonicated (50 watts for 30 s), boiled at  95 "C for 5 
min, and centrifuged at 10,000 X g for 5 min. The  supernatant was 
stored at -80 "C until assay of cGMP. The sediment was  lysed with 
1 N NaOH and used for protein determination.  Protein  determination 
was done according to Lowry et al. (30) using bovine serum albumin 
(Sigma) as a standard. cGMP was assayed with a commercially 
available radioimmunoassay (New England Nuclear). Cross-reactiv- 
ity between adenosine and cGMP was checked. Below M adeno- 
sine, no evidence for cross-reactivity was obtained. 
Guanylate Cycluse Assay-Guanylate cyclase activity was deter- 
mined according to Nesbitt  et al. (31) as modified by Ardaillou et al. 
(32). Guanylate cyclase activity was measured in homogenates of 
cultured smooth muscle cells, rat abdominal aorta, and bovine coro- 
nary artery. Cultured cells ( 107/ml) were sonicated at 50 watts for 30 
s in 2 ml of homogenization buffer (250 mM sucrose, 1 mM dithio- 
threitol, 25 mM Tris-HC1, pH 7.8). Aortas from male Sprague-Dawley 
rats  and pieces from bovine coronary arteries were thoroughly freed 
from adventitial tissue and subsequently homogenized in the homog- 
enization buffer using a  Polytron homogenizer. The homogenate thus 
obtained was further homogenized in a Dounce homogenizer (tight- 
fitting) with 30 strokes. In order to obtain  a  particulate and a soluble 
fraction, the homogenates were centrifuged at 100,000 X g for 1 h. 
The  supernatant was taken  as soluble fraction. The pellet was resus- 
pended in fresh homogenization buffer, sonicated, and taken as 
particulate fraction. 
Twenty microliters of homogenate or particulate/soluble fraction 
containing between 30 and 90  pg of protein were added to 100 p1 of 
reaction mixture containing 50 mM Tris-HC1, pH 7.8, 5 mM MnC12, 
5 mM MgCl?,  10 mM phosphocreatine, 150 pg of creatine kinase, 0.5 
mM GTP, 2.5 M cGMP, 0.25 mM papaverine, 0.1% bovine serum 
albumin, and 0.1 pCi of [CZ-~'P]GTP. Adenosine and its analogues 
were added in 10 pl of water. Incubation was performed for 10  min at 
37 "C. The reaction was stopped by adding 20 pl of 100 mM EDTA 
plus 100 nCi of [3H]cGMP. The solution was  boiled and centrifuged. 
[3ZP]~GMP was extracted from the supernatant using Dowex AG 
50WX4 (Bio-Rad) and neutral  alumina (M. Woelm,  Eschwege, Fed- 
eral Republic of Germany) columns exactly as described by Nesbitt 
et al. (31). 32P and 3H radioactivity were determined using Aquasol-2 
(New England Nuclear) as a  scintillant and a dual-label program on 
a Rackbeta &counter (LKB). Each experiment with the guanylate 
cyclase assay as shown under "Results" represents the mean of 
quadruplicates. Fig. 1 shows the time dependence and dependence on 
cellular protein of cGMP formation in assays performed in quadru- 
plicates. 
Agents-Adenosine, N6-cyclohexyladenosine (CHA), and  theoph- 
ylline were purchased from  Sigma. 5'-N-Ethylcarboxamidoadenosine 
(NECA) and M & B 22948 were generous gifts from Byk-Gulden 
Lamberg Chemische Fabrik, GmbH (Konstanz, Fedral Republic of 
Germany) and the May & Baker Co. (London, Great Britain), re- 
spectively. 
RESULTS 
In  order  to  ensure  that  the cells  used for the  experiments 
were SMC,  the existence of the  intermediate  filament  desmin 
in  the  cultured cells  was  checked.  Desmin is considered to be 
specific for myogenic cells in uiuo and in vitro (28) and does 
not occur in  endothelial cells or fibroblasts.  I found  that more 
than 90% of the  cultured cells stained positive for desmin, 
confirming that  the cells  used for experiments  are SMC. 
Cultured  SMC were incubated with  various concentrations 
of adenosine for 2, 5, and 15 min,  and  the cellular content of 
cyclic GMP was determined (Fig. 2).  It  can be seen from Fig. 
1 that adenosine led to a transient rise in cGMP levels at  
concentrations of adenosine ranging from IO-' to M. The 
rise in cGMPi occurred as soon as 2 min after addition of 
adenosine, which was the  first  time  point  examination. 
Fig. 3 shows the dependence of' cGMP levels observed after 
5 min on  the  concentration of adenosine  and of the adenosine 
analogues CHA and NECA. It  can be seen that  adenosine led 
to a 2.5-fold increase of cGMPi in  a dose-dependent fashion. 
In  order  to  find  out  whether or not  the effect of adenosine  is 
mediated by cell surface  receptors,  the effect of theophylline 
(a specific antagonist for  A-type receptors (33)) was examined. 
It  can be seen  in Fig. 2 that  in  the presence of theophylline 
(5 x M),  the dose-response curve of adenosine for cGMPi 
was shifted to the right by 2 orders of magnitude. Fig. 3 
further clarifies that  the effect of adenosine  on  cGMP could 
be mimicked by the A-type  receptor agonists CHA and NECA 
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FIG. 1. Formation of cGMP in guanylate cyclase assay sys- 
tem as functions of incubation time (left)  and  amount of added 
cellular protein (right). Data  are shown as mean k S.E. of quad- 
ruplicates. 0, experiments done in the absence of adenosine; *, 
experiment done in presence of adenosine M). Lines are linear 
regression curves. 
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FIG. 2. Time course of intracellular cGMP after addition of 
various concentrations of adenosine (ado) .  Data are mean f 
S.E. of 10 experiments. 
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FIG. 3. Dose dependence of intracellular cGMP on concen- 
tration of CHA, NECA, and adenosine (ado) in absence and 
presence of theophylline (5 X lo-' M). Cyclic nucleotides were 
determined 5 min after the addition of the agents.  Data ( X  f S.E. of 
10 experiments)  are  presented  as  percentage of the mean of control 
(i.e.  absence of agents). This form of plotting was  chosen  because of 
the scatter of control values  among the different  sets of experiments. 
Means of control  ranged  from 70 to 170  fmol/mg  cGMP. 
(33).  Concentrations required for  the  half-maximal effect on 
cGMPi were 6 X lo-' M for CHA and 1.2 X M for both 
adenosine  and NECA. Since  the effect of adenosine  on cGMP 
levels was observed exactly in the concentration range of 
adenosine  that  is typical  for  vasodilation (5-7), further  exper- 
iments were done in  order  to clarify the  mechanism by which 
adenosine could raise  cGMP levels. 
The cellular cGMP level in general is  determined by the 
activity of guanylate cyclases on the one hand and by the 
activity of cGMP  phosphodiesterases  on  the  other. To  find 
out  whether  or  not  adenosine influences  a cGMP  phosphodi- 
esterase,  combination  experiments of adenosine with the 
cGMP phosphodiesterase-specific inhibitor M & B 22948 (34) 
were performed (Table  I). As it  can be seen from Table I, M 
& B 22948 (1 mM) alone  had  no  significant effect on cGMPi. 
CHA M) elevated cGMP levels to  around  150% of 
control.  Combination of M & B 22948 and  adenosine led to 
an increase of cGMP  to  around 400% of control.  From  the 
finding  that  inhibition of cGMP  phosphodiesterase by M & 
B 22948 potentiated  the effect of adenosine  on cGMP levels, 
one  might  conclude that  adenosine elevates intracellular 
TABLE I 
Effect  of  cGMP  phosphodiesterase inhibitor M & B 22948 on rise  in 
cGMP;  evoked by adenosine 
cGMPi  was determined 5 min after the addition of the agents.  Data 
are mean f S.E. of eight  experiments. 
cCMP~ x of control 
jmollmg protein 
Control 93.5 f 16.3  00 
Adenosine (lo-' M) 146.7 f 26.3  156 
Adenosine ( lo-' M) plus 383.2 f 31.6  406 
M & B 22948 (1 mM) 111.7 f 15.2  119 
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FIG. 4. Dose dependence of guanylate cyclase activity in 
homogenates of cultured SMC on concentration of adenosine, 
CHA, and NECA added. Data  (mean f S.E. of five experiments) 
are  presented  as the percentage of the mean of control (ie. absence 
of agents).  Means of control  ranged  from  80 to 150 fmol of cGMP 
formed  per minlpg of protein. 
cGMP by the  stimulation of a guanylate cyclase rather  than 
by the  inhibition of a  phosphodiesterase. Therefore,  the effect 
of adenosine and its analogues (CHA and NECA) on gua- 
nylate cyclase activity of homogenated cultured SMC was 
investigated  (Fig. 4). I t  is  evident  from Fig. 4 that adenosine, 
CHA, and NECA led to a 2-2.5-fold increase in guanylate 
cyclase activity in a dose-dependent fashion. Half-maximal 
activation was observed at  4 X lo-' M for  CHA and 8 X 
M for both adenosine and NECA. Fig. 5 demonstrates that 
the  stimulation of guanylate cyclase activity by the  different 
adenosine analogues  (each at M) was prevented  in  the 
presence of  low concentrations of theophylline ( 5  X M ) .  
Guanylate cylase is known to occur in  both a  cytoplasmic 
(soluble) and a membrane-bound (particulate) form within 
vascular smooth muscle cells (24).  In  order  to  find  out  whether 
activation of cellular guanylate cyclase activity by adenosine 
Adenosine  and cGMP 6299 
without  with 
theophylline 
( ~ x ~ O - ~ M )  
E -  - Control  Ado CHA  NECA 
FIG. 5. Effects of adenosine (Ado) ,  CHA, and NECA (each 
at lo-' M) on guanylate cyclase activity  in homogenates of 
SMC in absence and presence of theophylline (5 x lo-" M). 
Data are mean ? S.E. The numbers at the bottom of the columns 
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FIG. 6. Effects of adenosine (Ado) ,  CHA, and NECA (each 
at lo-' M) on guanylate cyclase  activity present in supernatant 
(soluble) and particulate fractions of homogenized cultured 
SMC. Data  are mean ? S.E. of 10 experiments. 
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FIG. 7. Formation of cGMP in guanylatecyclase  assay assay 
system by soluble (circles) and particulate (triangles) gua- 
nylate  cyclases as a function of added protein. Open symbols, 
experiments done in the absence of adenosine; closed symbols, exper- 
iments done in the presence of adenosine (10- M). Data  are mean of 
quadruplicates. 
is  due  to  the  stimulation of a soluble or a particulate  guanylate 
cyclase activity,  the effects of adenosine, CHA, and NECA on 
guanylate cyclase activity present in the supernatant and 
particulate  fractions of the cell homogenate was further  ex- 
amined. Fig. 6 shows that  adenosine, CHA, and NECA (all 
M)  stimulated  guanylate cyclase activity  in  the  particu- 
late  fraction  and failed to affect guanylate cyclase activity in 
the  supernatant  fractions. Fig. 7 documents  that  cGMP  for- 
mation in the  guanylate cyclase assay by both  the soluble and 
particulate  guanylate cyclases was linearly dependent  on  the 
amount of protein. 
DISCUSSION 
The objective of this  study was to  find  out  whether  or  not 
an  alteration of the  intracellular level of cGMP could be a 
way of signal transmission through which adenosine could 
induce relaxation  in vascular smooth muscle cells. Since 
cGMP  is known as a  second  messenger  for  vasodilation, the 
effect of adenosine  on  the cellular level of this cyclic nucleo- 
tide was investigated in  cultures of vascular SMC from rat 
aorta. 
The  relaxant effect of adenosine typically  occurs at  lo-' to 
M (5-7).  Clear  evidence is provided in  the  present  study 
that adenosine elevates cGMP levels in this concentration 
range (Fig. 3). Adenosine was found to elevate cGMP  about 
2-%fold over control.  Sodium  nitroprusside (1O"j  M) elevated 
cGMPi  around %fold over control  in  the  same  cultures  (data 
not  shown),  and  this is the value found for nitrocompounds 
in vascular tissues in vitro (35). If one accepts that the 
vasorelaxant effect of nitrocompounds  is  mediated by a  rise 
in  cGMPi,  then  the rise of cGMPi observed in  the presence of 
adenosine would be sufficient to explain its  relaxant effect. I t  
was further found in  this  study  that  the effect of adenosine 
could be mimicked by CHA and NECA, which are adenosine 
analogues that specifically bind  to A-type receptors  (33) (Fig. 
3) .  In  addition,  it was demonstrated  that  the effect of adeno- 
sine  on  cGMP, could be  antagonized by low concentrations of 
theophylline, which is considered an  antagonist of A-type cell 
surface receptors of adenosine (33). Taken together, both 
findings suggest that the effect of adenosine on cGMPi is 
mediated by AI-type cell surface receptors. This conclusion 
would be in  harmony  with  the  experimental evidence that  the 
vasorelaxing effect of adenosine is mediated by cell surface 
receptors (8,9) that  can  be antagonized by theophylline (10). 
A-type receptors  are  separated in two subclasses: AI- and 
A,-receptors. So far, highly specific agonists for both receptor 
types  are  not available. It  has been  shown, however, that  there 
exists  an  order of specificity of receptor binding  among dif- 
ferent  adenosine derivatives. CHA has been found to have  a 
higher affinity for A,-receptors  than does NECA, whereas  the 
opposite is true for A,-receptors (33). The finding that  the 
dose-response  curve of CHA for cGMPi is shifted  to  the left 
in comparison to that of NECA (Fig. 3) suggests that the 
effect of adenosine  on cGMPi is mediated by AI-receptors. 
Three pieces of evidence were obtained in this study to 
indicate  that  adenosine raises  cGMPi levels by the  stimulation 
of a membrane-bound guanylate cyclase. First,  inhibition of 
cGMP  phosphodiesterase  potentiated  the effect of adenosine 
on cGMPi (Table I). Second, adenosine, CHA, and NECA 
stimulated cellular guanylate cyclase activity in a dose de- 
pendent  fashion (Fig. 4). The  stimulatory effect of adenosine 
and its derivatives on guanylate cyclase activity could be 
prevented by the A-type receptor antagonist theophylline 
(Fig. 5). In parallel with the effect on  cGMPi,  the  order of 
potency on  guanylate cyclase activity again was CHA > 
NECA. Third,  adenosine, CHA, and NECA stimulated  guan- 
ylate cyclase activity  in  the  particulate  fraction  but failed to 
affect soluble guanylate cyclase activity (Fig. 6). Stimulation 
of a membrane-bound  guanylate cyclase by adenosine would 
in  turn be in  harmony  with  the vidence that  the vasorelaxing 
effect of adenosine is mediated by cell surface receptors. 
Taken together, the data obtained in this study strongly 
suggest that occupancy of AI-receptors  stimulates a guanylate 
cyclase in vascular smooth muscle cells. Since  cGMP  is known 
6300 Adenosine 
as a  second  messenger mediating  vasorelaxation, my results 
indicate that cGMP could have an important role in the 
vasodilation  induced by adenosine.  In  order  to  find  out 
whether  or  not  activation of guanylate cyclase by adenosine 
is a  more  general  vascular phenomenon, I  have  also  examined 
the effect of adenosine  on  guanylate cyclase activity  in ho- 
mogenates of rat  aorta, bovine coronary  artery,  and  cultured 
SMC from calf aorta  (data  not  shown). Also in  these  prepa- 
rations, I found a dose-dependent stimulation of guanylate 
cyclase activity by adenosine. Concentrations of adenosine 
required for  half-maximal  effects were 2 X 2.5 X 
and 4 X M for  at  aorta, bovine coronary  artery,  and 
SMC from calf aorta, respectively. 
Whether  or  not a  coupling  between Al-receptors  and gua- 
nylate cyclase also exists  in cell types  different from  typical 
vascular smooth muscle cells remains to be clarified. If so, 
then  it would be interesting  to  test  whether  or  not A,-receptor- 
mediated effects of adenosine, such as inhibition of renin 
release  from renal  juxtaglomerular cells (36) or  the negative 
chronotropy  in myocardial cells (37), are due to  the  activation 
of a guanylate cyclase. I t  might  be of interest  in  this  context 
that  cGMP  has recently  been  found to be a strong  inhibitory 
signal  for renin release  from renal  juxtaglomerular cells (38). 
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